Escalating-dose HLA-mismatched DLI is safe for the treatment of leukaemia relapse following alemtuzumab-based myeloablative allo-SCT

Bone Marrow Transplantation

Volumn 48, Issue 10, 2013, Pages 1324-1328

  Innes, A J ^a   Beattie, R ^b   Sergeant, R ^b   Damaj, G ^a   Foroni, L ^a   Marin, D ^a   Kanfer, E ^a   Mielke, S ^c   Milojkovic, D ^a   Macdonald, D ^a   Pavlu, J ^a   Rahemtulla, A ^b   Roberts, I ^a   Slade, D ^b   Bray, E ^b   Goldman, J ^a   Apperley, J ^a   Szydlo, R ^a   Dazzi, F ^a   Rezvani, K ^a,d  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b HAMMERSMITH HOSPITAL   (United Kingdom)

^c UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

DLI; GVHD; relapse

Indexed keywords

ALEMTUZUMAB; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; DACLIZUMAB; ETOPOSIDE; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID; PREDNISOLONE;

ACUTE GRAFT VERSUS HOST DISEASE; ACUTE GRANULOCYTIC LEUKEMIA; ADJUVANT THERAPY; ADOLESCENT; ADULT; ARTICLE; AUTOIMMUNE HEMOLYTIC ANEMIA; BLOOD SAFETY; BONE MARROW TRANSPLANTATION; CANCER SURVIVAL; CHRONIC GRAFT VERSUS HOST DISEASE; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; DONOR LYMPHOCYTE INFUSION; FEMALE; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HLA MATCHING; HLA TYPING; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; MAJOR CLINICAL STUDY; MALE; MATCHED UNRELATED DONOR; MISMATCHED UNRELATED DONOR; MYELOABLATIVE CONDITIONING; OVERALL SURVIVAL; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SAFETY; SURVIVAL RATE; T CELL DEPLETION; TIME TO TREATMENT; UNRELATED DONORS; WHOLE BODY RADIATION;

ADOLESCENT; ADULT; ANTIBODIES, MONOCLONAL, HUMANIZED; FEMALE; HISTOCOMPATIBILITY; HLA ANTIGENS; HUMANS; LEUKEMIA; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; RETROSPECTIVE STUDIES; STEM CELL TRANSPLANTATION; T-LYMPHOCYTES; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84885599167     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2013.69     Document Type: Article

References (27)

1. Pavlu J, Szydlo RM, Goldman JM, Apperley J. Three decades of transplantation for chronic myeloid leukaemia: what have we learned? Blood 2011; 117: 755-763.
2. Baldomero H, Gratwohl M, Gratwohl A, Tichelli A, Niederwieser D, Madrigal A et al. The EBMT activity survey 2009: trends over the past 5 years. Bone Marrow Transplant 2011; 46: 485-501.
3. Craddock CF. Full-intensity and reduced intensity allogeneic stem cell transplantation in AML. Bone marrow Transplant 2008; 31: 415-423. (Pubitemid 351386707)
4. Ballen KK, Korelth J, Yi-Bin Chen, Dey BR, Spitzer TR. Selection of optimal alternative graft source: mismatched unrelated donor, umbilical cord blood, or haploidentical transplantation. Blood 2012; 119: 1972-1980.
5. Oudshoorn M, van Walraven SM, Bakker JN, Lie JL, V D Zanden HG, Heemskerk MB et al. Hematopoietic stem cell donor selection: the Europdonor experience. Hum Immunol 2006; 67: 405-412. (Pubitemid 44226305)
6. Mead AJ, Thomas KJ, Morris EC, Mohamedbhai S, Denovan S, Orti G et al. HLAmismatched unrelated donors are a viable alternative graft source for allogeneic transplantion following alemtuzumab-based reduced-intensity conditioning. Blood 2010; 115: 5147-5153.
7. Yagasaki H, Kojima S, Yabe H, Kato K, Kigasawa H, Sakamaki H et al. Acceptable HLA-matching in unrelated donor bone marrow transplantation for patients with acquired severe aplastic anaemia. Blood 2011; 118: 3186-3190.
8. Arora M, Weisdorf DJ, Spellman SR, Haagenson MD, Klein JP, Hurley CK et al. HLA-identical sibling compared with 8/8 matched and mismatched unrelated donor bone marrow transplant for chronic phase chronic myeloid leukemia. J Clin Oncol 2009; 27: 1644-1652.
9. Yeung DT, Parker WT, Branford S. Molecular methods in diagnosis and monitoring of haematological malignancies. Pathology 2011; 43: 566-579.
10. Bene MC, Kaeda JS. How and why minimal residual disease studies are necessary in leukaemia: a review from WP10 and WP12 of the European Leukaemia Net. Haematologica 2009; 94: 1135-1150.
11. Kolb HJ, Schattenberg A, Goldman JM, Hertenstein B, Jacobsen N, Arcese W et al. Graft-versus-leukaemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood 1995; 86: 2041-2050.
12. Dazzi F, Szydlo RM, Cross NC, Craddock C, Kaeda J, Kanfer E et al. Durability of responses following donor lymphocyte infusions for patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukaemia. Blood 2000; 96: 2712-2716.
13. Roos-Weil D, Nguyen S, Uzunov M, Bories D, Chapiro E, Nguyen-Khac F et al. Therapy-related myelodysplastic syndrome after allogeneic BMT: successful treatment by donor lymphocyte infusions. Bone Marrow Transplant 2010; 45: 1471-1473.
14. Loren AW, Porter DL. Donor leukocyte infusions for the treatment of relapsed acute leukemia after allogeneic stem cell transplantation. Bone Marrow Transplant 2008; 41: 483-493. (Pubitemid 351386713)
15. Toor A, Rodriguez T, Bauml M, Mathews H, Shanti S, Senitzer D et al. Feasibility of conditioning with thymoglobulin and reduced intensity TBI to reduce acute GVHD in recipients of allogeneic SCT. Bone Marrow Transplant 2008; 42: 723-731.
16. Kim HJ, Min WS, Cho BS. Successful prevention of acute graft-versus-host disease using low-dose antithymocyte globulin after mismatched, unrelated, hematopoietic stem cell transplantation for acute myelogenous leukemia. Biol Blood Marrow Transplant 2009; 15: 704-717.
17. Or R, Hadar E, Bitan M, Resnick IB, Aker M, Ackerstein A et al. Safety and efficacy of donor lymphocyte infusions following mismatched stem cell transplantation. Biol Blood Marrow Transplant 2006; 12: 1295-1301. (Pubitemid 44858263)
18. Prepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J et al. 1994 Consensus conference in acute GVHD grading. Bone Marrow Transplant 1995; 15: 825-828.
19. Glucksberg H, Storb R, Fefer A, Buckner CD, Neiman PE, Clift RA et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation 1974; 18: 295-303.
20. Hanahan D, Weinberd R. Hallmarks of cancer: the next generation. Cell 2011; 144: 646-676.
21. Simula MP, Marktel S, Fozza C, Kaeda J, Szydlo RM, Nadal E et al. Response to donor lymphocyte infusions for chronic myeloid leukemia is dose-dependent: the importance of escalating the cell dose to maximize therapeutic efficacy. Leukemia 2007; 21: 943-948. (Pubitemid 46672070)
22. Rizzieri DA, Dev P, Long GD, Gasparetto C, Sullivan KM, Horwitz M et al. Response and toxicity of donor lymphocyte infusions following T-cell depleted non-myeloablative allogeneic hematopoietic SCT from 3-6/6 HLA matched donors. Bone Marrow Transplant 2009; 43: 327-333.
23. Huang XJ, Liu DH, Liu KY, Xu LP, Chen YH, Wang Y et al. Modified donor lymphocyte infusion after HLA-mismatched/haploidentical T cell-replete hematopoietic stem cell transplantation for prophylaxis of relapse of leukemia in patients with advanced leukemia. J Clin Immunol 2008; 28: 276-283.
24. Basak GW, de Wreede LC, van Biezen A, Wiktor-Jedrzejczak W, Halaburda K, Schmid C et al. Donor lymphocyte infusions for the treatment of chronic myeloid leukemia relapse following peripheral blood or bone marrow stem cell transplantation. Bone Marrow Transplant 2013; 48: 837-842.
25. Peggs KS, Thomson K, Hart DP, Geary J, Morris EC, Yong K et al. Dose-escalated donor lymphocyte infusions following reduced intensity transplantation: toxicity, chimerism, and disease responses. Blood 2004; 103: 1548-1556. (Pubitemid 38168677)
26. Olavarria E, Siddique S, Griffiths MJ, Avery S, Byrne JL, Piper KP et al. Posttransplantation imatinib as a strategy to postpone the requirement for immunotherapy in patients undergoing reduced-intensity allografts for chronic myeloid leukemia. Blood 2007; 110: 4614-4617. (Pubitemid 351377831)
27. Schroeder T, Czibere A, Platzbecker U, Bug G, Uharek L, Luft T et al. Azacitidine and donor lymphocyte infusions as first salvage therapy for relapse of AML or MDS allogeneic stem cell transplantation. Leukemia 2013; 27: 1229-1235.